Literature DB >> 23766830

Laparoscopic partial nephrectomy for >4 cm renal masses.

Fahad A Alyami1, Ricardo A Rendon.   

Abstract

INTRODUCTION: Laparoscopic partial nephrectomy (LPN) is frequently used to manage cT1a renal masses. While data on safety and long-term oncological outcomes of LPN for T1a tumours are widely available, it is limited for >T1a lesions. We report our experience with LPN for >4 cm renal masses from a Canadian tertiary centre.
METHODS: Between January 2003 and July 2011, 52 consecutive LPN for >4 cm renal masses were performed. Demographic, pathological and clinical data were obtained from a prospectively maintained database.
RESULTS: The mean patient age was 60 years (62% male). Median tumour size was 4.8 (range: 4.2-11) cm. The median surgical time was 145 minutes, and the median estimated blood loss was 100 mL. The median warm ischemia time was 24 minutes. Four (7.7%) cases required conversion to open surgery. One case was converted to total nephrectomy for clinical and pathological evidence of T3 disease. The surgical margin was positive in 1 case (1.9%). Four (7.7%) patients developed a urine leak postoperatively; 3 of them managed with a ureteric stent. Four (7.7%) patients developed postoperative bleeding requiring selective angioembolization. The median hospital stay was 4 days. There was no statistically significant difference between preoperative and postoperative estimated glomerular filtration rate and mean arterial blood pressure (p = 0.5, p = 0.1, respectively).
CONCLUSION: This series demonstrates that LPN although technically challenging has acceptable short-term surgical outcomes. Long-term assessment of oncological outcomes is required. Laparoscopic partial nephrectomy >4 cm renal tumours should not be considered a standard of care, but excellent results can be achieved in well-selected patients and in experienced hands with no impact in renal function or blood pressure.

Entities:  

Year:  2013        PMID: 23766830      PMCID: PMC3668399          DOI: 10.5489/cuaj.1003

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  26 in total

1.  Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm.

Authors:  Frank Becker; Stefan Siemer; Markus Hack; Ulrich Humke; Manfred Ziegler; Michael Stöckle
Journal:  Eur Urol       Date:  2006-03-23       Impact factor: 20.096

2.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.

Authors:  William C Huang; Andrew S Levey; Angel M Serio; Mark Snyder; Andrew J Vickers; Ganesh V Raj; Peter T Scardino; Paul Russo
Journal:  Lancet Oncol       Date:  2006-09       Impact factor: 41.316

3.  Does tumour size really affect the safety of laparoscopic partial nephrectomy?

Authors:  Francesco Porpiglia; Cristian Fiori; Riccardo Bertolo; Roberto Mario Scarpa
Journal:  BJU Int       Date:  2010-11-02       Impact factor: 5.588

4.  Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup.

Authors:  A F Fergany; K S Hafez; A C Novick
Journal:  J Urol       Date:  2000-02       Impact factor: 7.450

Review 5.  The epidemiology of renal cell carcinoma.

Authors:  Loren Lipworth; Robert E Tarone; Joseph K McLaughlin
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

6.  Laparoscopic versus open partial nephrectomy for the treatment of pathological T1N0M0 renal cell carcinoma: a 5-year survival rate.

Authors:  Sompol Permpongkosol; Herman S Bagga; Frederico R Romero; Myrna Sroka; Thomas W Jarrett; Louis R Kavoussi
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

7.  Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience.

Authors:  Jean-Jacques Patard; Oleg Shvarts; John S Lam; Allan J Pantuck; Hyung L Kim; Vincenzo Ficarra; Luca Cindolo; Ken-Ryu Han; Alexandre De La Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; Dominique K Chopin; Robert A Figlin; Peter F A Mulders; Arie S Belldegrun
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

8.  Laparoscopic partial nephrectomy for centrally located renal tumors.

Authors:  Igor Frank; Jose R Colombo; Mauricio Rubinstein; Mihir Desai; Jihad Kaouk; Inderbir S Gill
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

9.  Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger.

Authors:  Robert E Mitchell; Scott M Gilbert; Alana M Murphy; Carl A Olsson; Mitchell C Benson; James M McKiernan
Journal:  Urology       Date:  2006-02       Impact factor: 2.649

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  4 in total

1.  Report on Advances for General Medicine in 2019: Neurosurgery, Urology, Gynecology and Obstetrics, and Internal Medicine.

Authors:  Hakan Doneray
Journal:  Eurasian J Med       Date:  2020-06

2.  Comparison of survival and renal function between partial and radical laparoscopic nephrectomy for T1b renal cell carcinoma.

Authors:  Feiya Yang; Qiang Zhou; Nianzeng Xing
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-01       Impact factor: 4.553

3.  The Use of Three Different Hemostatic Agents during Laparoscopic Partial Nephrectomy: A Comparison of Surgical and Early Renal Functional Outcomes.

Authors:  Serdar Aykan; Mustafa Zafer Temiz; Ismail Ulus; Mehmet Yilmaz; Serkan Gonultas; Serhat Suzan; Atilla Semercioz; Ahmet Yaser Muslumanoglu
Journal:  Eurasian J Med       Date:  2019-06

4.  Laparoscopic partial nephrectomy for multilocular cystic renal cell carcinoma: a potential gold standard treatment with excellent perioperative outcomes.

Authors:  Ben Xu; Yue Mi; Li-qun Zhou; Jie Jin; Qian Zhang; Guang-fu Chen
Journal:  World J Surg Oncol       Date:  2014-04-23       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.